Findings of Research Misconduct, 23600 [2011-10157]
Download as PDF
<![CDATA[
23600
Federal Register / Vol. 76, No. 81 / Wednesday, April 27, 2011 / Notices
Guidelines to Agencies on
Governmentwide Debarment and
Suspension (2 CFR 376 et seq.); and
(2) Dr. Bhrigu is prohibited from
serving in any advisory capacity to the
U.S. Public Health Service (PHS),
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–10150 Filed 4–26–11; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Junghee J. Shin, PhD, New York
Medical College: Based on the report of
an investigation conducted by New
York Medical College (NYMC) and
additional analysis by the Office of
Research Integrity (ORI) in its oversight
review, the U.S. Public Health Service
(PHS) found that Junghee J. Shin, PhD,
former graduate student, NYMC,
engaged in research misconduct in
research supported by National Institute
of Allergy and Infectious Diseases
(NIAID), National Institutes of Health
(NIH), grants R01 AI048856 and R01
AI043063.
PHS found that the Respondent
engaged in research misconduct by
falsifying data in Figure 4 of a
manuscript submitted to the journal
Infection and Immunity (Shin, J.J.,
Godfrey, H.P., & Cabello, F.C.
‘‘Expression and localization of BmpC in
Borrelia burgdorferi after growth under
various environmental conditions.’’
Submitted to Infection and Immunity;
hereafter referred to as the
‘‘manuscript’’) and Figure 5 of a paper
published in Infection and Immunity
(Shin, J.J. Bryksin, A.V., Godfrey, H.P.,
& Cabello, F.C. ‘‘Localization of BmpA
on the exposed outer membrane of
Borrelia burgdorferi by monospecific
anti-recombinant BmpA rabbit
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:36 Apr 26, 2011
Jkt 223001
antibodies.’’ Infection and Immunity
72(4):2280–2287, April 2004; hereafter
referred to as the ‘‘paper.’’ Retracted in:
Infection and Immunity 76(10):4792,
October 2008). Specifically, NYMC and
ORI found that:
• Dr. Shin falsified microscopic
immunofluorescence blank images in
Figure 4 of the manuscript (top row, 1st,
2nd, 4th, and 5th panels, and bottom
row, 1st panel) and Figure 5 of the paper
(top row, 1st and 5th panels, lower 1st
panel) by using one blank image from an
unknown experiment to falsely
represent the preimmunization control
conditions (intact cells and methanol
fixation) as well as the negative staining
of anti-BmpC and anti-FlaB in Figure 4
and anti-FlaB in Figure 5 on intact cells.
• Dr. Shin falsified at least one of two
images in Figure 4 of the manuscript
and Figure 5 of the paper by using
different portions of a green-red pair of
microscopic immunofluorescence
images (1230036.tif and 1230037.tif)
because unfixed cells staining positive
for BmpA in the top row, 4th panel, of
Figure 5 were the same unfixed cells
purportedly positive for OspA in the top
row, 3rd panel, of Figure 4.
• Dr. Shin falsified at least one of two
images in Figure 4 of the manuscript
and Figure 5 of the paper by using
different photo cropping from a single
microscopic immunofluorescence image
(1230039.tif) to represent fixed cells
positive for BmpA and labeled with
anti-FlaB in the lower row, 5th panel, of
Figure 5 and to also represent fixed cells
positive for BmpC and stained with
anti-FlaB in the lower row, 5th panel, of
Figure 4.
Dr. Shin has entered into a Voluntary
Settlement Agreement in which she has
voluntarily agreed, for a period of three
(3) years, beginning on April 5, 2011:
(1) That any institution that submits
an application for PHS support for a
research project on which the
Respondent’s participation is proposed
or that uses her in any capacity on PHSsupported research, or that submits a
report of PHS-funded research in which
she is involved, must concurrently
submit a plan for supervision of her
duties to ORI for approval; the
supervisory plan must be designed to
ensure the scientific integrity of her
research contribution; Respondent
agrees that she will not participate in
any PHS-supported research until such
a supervision plan is submitted to ORI;
and
(2) to exclude herself voluntarily from
service in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–10157 Filed 4–26–11; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[CDC–2011–0005]
Availability of Draft Toxicological
Profile
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (DHHS).
ACTION: Notice of availability.
AGENCY:
This notice announces the
availability of the Toxicological Profile
for Uranium (Update) for review and
comment. These comments can include
additional information or reports on
studies about the health effects of
uranium. Although ATSDR considered
key studies for uranium during the
profile development process, this
Federal Register notice solicits any
relevant, additional studies, particularly
unpublished data. ATSDR will evaluate
the quality and relevance of such data
or studies for possible addition to the
profile. ATSDR remains committed to
providing a public comment period for
this document as a means to best serve
public health and our clients.
The Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA), as amended by
the Superfund Amendments and
Reauthorization Act of 1986 (SARA),
§ 104(i)(3), [42 U.S.C. 9604(i)(3)], directs
the ATSDR administrator to prepare
toxicological profiles of priority
hazardous substances and, as necessary,
to revise and publish each updated
toxicological profile.
DATES: To be considered, comments on
this draft toxicological profile must be
received not later than July 29th, 2011.
Comments received after the close of the
public comment period will be
considered at the discretion of ATSDR,
based upon what is deemed to be in the
best interest of the general public.
ADDRESSES: Requests for printed copies
of the draft toxicological profile should
be sent via e-mail to cdcinfo@cdc.gov, or
SUMMARY:
E:\FR\FM\27APN1.SGM
27APN1
]]>Agencies
[Federal Register Volume 76, Number 81 (Wednesday, April 27, 2011)]
[Notices]
[Page 23600]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10157]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Junghee J. Shin, PhD, New York Medical College: Based on the report
of an investigation conducted by New York Medical College (NYMC) and
additional analysis by the Office of Research Integrity (ORI) in its
oversight review, the U.S. Public Health Service (PHS) found that
Junghee J. Shin, PhD, former graduate student, NYMC, engaged in
research misconduct in research supported by National Institute of
Allergy and Infectious Diseases (NIAID), National Institutes of Health
(NIH), grants R01 AI048856 and R01 AI043063.
PHS found that the Respondent engaged in research misconduct by
falsifying data in Figure 4 of a manuscript submitted to the journal
Infection and Immunity (Shin, J.J., Godfrey, H.P., & Cabello, F.C.
``Expression and localization of BmpC in Borrelia burgdorferi after
growth under various environmental conditions.'' Submitted to Infection
and Immunity; hereafter referred to as the ``manuscript'') and Figure 5
of a paper published in Infection and Immunity (Shin, J.J. Bryksin,
A.V., Godfrey, H.P., & Cabello, F.C. ``Localization of BmpA on the
exposed outer membrane of Borrelia burgdorferi by monospecific anti-
recombinant BmpA rabbit antibodies.'' Infection and Immunity
72(4):2280-2287, April 2004; hereafter referred to as the ``paper.''
Retracted in: Infection and Immunity 76(10):4792, October 2008).
Specifically, NYMC and ORI found that:
Dr. Shin falsified microscopic immunofluorescence blank
images in Figure 4 of the manuscript (top row, 1st, 2nd, 4th, and 5th
panels, and bottom row, 1st panel) and Figure 5 of the paper (top row,
1st and 5th panels, lower 1st panel) by using one blank image from an
unknown experiment to falsely represent the preimmunization control
conditions (intact cells and methanol fixation) as well as the negative
staining of anti-BmpC and anti-FlaB in Figure 4 and anti-FlaB in Figure
5 on intact cells.
Dr. Shin falsified at least one of two images in Figure 4
of the manuscript and Figure 5 of the paper by using different portions
of a green-red pair of microscopic immunofluorescence images
(1230036.tif and 1230037.tif) because unfixed cells staining positive
for BmpA in the top row, 4th panel, of Figure 5 were the same unfixed
cells purportedly positive for OspA in the top row, 3rd panel, of
Figure 4.
Dr. Shin falsified at least one of two images in Figure 4
of the manuscript and Figure 5 of the paper by using different photo
cropping from a single microscopic immunofluorescence image
(1230039.tif) to represent fixed cells positive for BmpA and labeled
with anti-FlaB in the lower row, 5th panel, of Figure 5 and to also
represent fixed cells positive for BmpC and stained with anti-FlaB in
the lower row, 5th panel, of Figure 4.
Dr. Shin has entered into a Voluntary Settlement Agreement in which
she has voluntarily agreed, for a period of three (3) years, beginning
on April 5, 2011:
(1) That any institution that submits an application for PHS
support for a research project on which the Respondent's participation
is proposed or that uses her in any capacity on PHS-supported research,
or that submits a report of PHS-funded research in which she is
involved, must concurrently submit a plan for supervision of her duties
to ORI for approval; the supervisory plan must be designed to ensure
the scientific integrity of her research contribution; Respondent
agrees that she will not participate in any PHS-supported research
until such a supervision plan is submitted to ORI; and
(2) to exclude herself voluntarily from service in any advisory
capacity to PHS, including but not limited to service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John Dahlberg,
Director, Division of Investigative Oversight, Office of Research
Integrity.
[FR Doc. 2011-10157 Filed 4-26-11; 8:45 am]
BILLING CODE 4150-31-P
